Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03796637 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren

A Phase 2 study of Duchenne Muscular Dystrophy, sponsored by PTC Therapeutics.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT03796637 is a Phase 2 study of Duchenne Muscular Dystrophy that has completed, run by PTC Therapeutics. The registered enrollment target is 6 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03796637, a Phase 2 study of Duchenne Muscular Dystrophy, has completed, sponsored by PTC Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This study is designed to generate additional data on the effect of ataluren for producing dystrophin protein in nonsense mutation nmDMD participants. This study will evaluate dystrophin levels from participants with nmDMD who currently have been receiving ataluren for ≥9 months. The study will have a single visit (Visit 1).

Conditions Studied

Duchenne Muscular Dystrophy

Interventions

  • DRUG Ataluren

Study Locations (1)

California

  • University of California, Los Angeles (UCLA) - Los Angeles

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2019-04-11
Est. Completion 2019-06-03
Phase Phase 2

Sponsor

PTC Therapeutics

52 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03796637

The ClinicalTrials.gov registry entry for NCT03796637 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (99% lower). The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Ataluren is the first listed.

NCT03796637 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03796637 about?

NCT03796637 is a clinical study titled "A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren". This study is designed to generate additional data on the effect of ataluren for producing dystrophin protein in nonsense mutation nmDMD participants. This study will evaluate dystrophin levels from participants with nmDMD who currently have been receiving ataluren for ≥9 months. The study will hav...

What is the current status of trial NCT03796637?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-04-11. Estimated completion is 2019-06-03.

What conditions does trial NCT03796637 study?

This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.

What interventions are being tested in trial NCT03796637?

The interventions under investigation include: Ataluren (DRUG).

Who is sponsoring clinical trial NCT03796637?

This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03796637 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Duchenne Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Duchenne Muscular Dystrophy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.